Meyka Pro banner
Alivus Life Sciences Limited

Alivus Life Sciences Limited Fundamental Analysis (BSE: ALIVUS.BO)

ALIVUS.BO●BSE
HealthcareDrug Manufacturers - Specialty & Generic
₹1434.15
₹15.70(1.08%)
Indian Market opens in 38h 20m

Alivus Life Sciences Limited Fundamental Analysis (BSE: ALIVUS.BO)

Alivus Life Sciences Limited (BSE: ALIVUS.BO) shows strong financial fundamentals with a PE ratio of 26.35, profit margin of 24.95%, and ROE of 20.14%. The company generates $26.9B in annual revenue with moderate year-over-year growth of 7.59%.

Key Strengths

ROE20.14%
Operating Margin31.31%
Current Ratio5.08

Areas of Concern

No major concerns flagged.
We analyze ALIVUS.BO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 87.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B+
87.4/100

We analyze ALIVUS.BO's fundamental strength across five key dimensions:

Efficiency Score

Excellent

ALIVUS.BO demonstrates superior asset utilization.

ROA > 10%
15.42%

Valuation Score

Moderate

ALIVUS.BO shows balanced valuation metrics.

PE < 25
26.35
PEG Ratio < 2
1.01

Growth Score

Excellent

ALIVUS.BO delivers strong and consistent growth momentum.

Revenue Growth > 5%
7.59%
EPS Growth > 10%
16.05%

Financial Health Score

Excellent

ALIVUS.BO maintains a strong and stable balance sheet.

Debt/Equity < 1
0.01
Current Ratio > 1
5.08

Profitability Score

Excellent

ALIVUS.BO achieves industry-leading margins.

ROE > 15%
20.14%
Net Margin ≥ 15%
24.95%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ALIVUS.BO Expensive or Cheap?

P/E Ratio

ALIVUS.BO trades at 26.35 times earnings. This indicates a fair valuation.

26.35

PEG Ratio

When adjusting for growth, ALIVUS.BO's PEG of 1.01 indicates fair valuation.

1.01

Price to Book

The market values Alivus Life Sciences Limited at 4.86 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.86

EV/EBITDA

Enterprise value stands at 18.27 times EBITDA. This signals the market has high growth expectations.

18.27

How Well Does ALIVUS.BO Make Money?

Net Profit Margin

For every $100 in sales, Alivus Life Sciences Limited keeps $24.95 as profit after all expenses.

24.95%

Operating Margin

Core operations generate 31.31 in profit for every $100 in revenue, before interest and taxes.

31.31%

ROE

Management delivers $20.14 in profit for every $100 of shareholder equity.

20.14%

ROA

Alivus Life Sciences Limited generates $15.42 in profit for every $100 in assets, demonstrating efficient asset deployment.

15.42%

Following the Money - Real Cash Generation

Operating Cash Flow

Alivus Life Sciences Limited generates limited operating cash flow of $2.61B, signaling weaker underlying cash strength.

$2.61B

Free Cash Flow

Alivus Life Sciences Limited produces free cash flow of $1.48B, offering steady but limited capital for shareholder returns and expansion.

$1.48B

FCF Per Share

Each share generates $12.03 in free cash annually.

$12.03

FCF Yield

ALIVUS.BO converts 0.84% of its market value into free cash.

0.84%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

26.35

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.01

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.86

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.58

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.20

vs 25 benchmark

ROA

Return on assets percentage

0.15

vs 25 benchmark

ROCE

Return on capital employed

0.22

vs 25 benchmark

How ALIVUS.BO Stacks Against Its Sector Peers

MetricALIVUS.BO ValueSector AveragePerformance
P/E Ratio26.3530.24 Better (Cheaper)
ROE20.14%540.00% Weak
Net Margin24.95%-2322.00% (disorted) Strong
Debt/Equity0.010.08 Strong (Low Leverage)
Current Ratio5.085.59 Strong Liquidity
ROA15.42%-17516.00% (disorted) Strong

ALIVUS.BO outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alivus Life Sciences Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

7.41%

Industry Style: Defensive, Growth, Innovation

Growing

EPS CAGR

16.05%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

37.39%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ